Cargando…
Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation
OBJECTIVE: To summarise the evidence on effectiveness of non-pharmacological (ie, non-drug, non-surgical) interventions on work participation (sick leave, work status and presenteeism) in people with rheumatic and musculoskeletal diseases (RMDs). METHODS: A systematic review of randomised controlled...
Autores principales: | Butink, Maarten H P, Webers, Casper, Verstappen, Suzanne M M, Falzon, Louise, Betteridge, Neil, Wiek, Dieter, Woolf, Anthony D, Stamm, Tanja A, Burmester, Gerd R, Bijlsma, Johannes W J, Christensen, Robin, Boonen, Annelies |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098260/ https://www.ncbi.nlm.nih.gov/pubmed/36596655 http://dx.doi.org/10.1136/rmdopen-2022-002903 |
Ejemplares similares
-
Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider
por: Marques, Mary Lucy, et al.
Publicado: (2021) -
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis
por: Boonen, Annelies, et al.
Publicado: (2021) -
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022) -
Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases
por: Marques, Andréa, et al.
Publicado: (2022) -
Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)